









Markets
/
Stocks
/
nasdaq-mira
/

Mira Pharmaceuticals Inc

MIRA

1.530USD

-0.040-2.55%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

26.60MMarket Cap

LossP/E TTM



Mira Pharmaceuticals Inc

1.530

-0.040-2.55%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mira Pharmaceuticals Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mira Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

166 / 407

Overall Ranking

303 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

3.000

Target Price

+91.08%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mira Pharmaceuticals Inc Highlights

StrengthsRisks

MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD). Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia.

Undervalued

The company’s latest PE is -3.26, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 994.82K shares, decreasing 36.32% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 117.82K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.86.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.04, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.04

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Mira Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 5.76, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -3.26, which is -80.76% below the recent high of -0.63 and -77.70% above the recent low of -5.80.

Score

Industry at a Glance

Previous score

5.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 166/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for Mira Pharmaceuticals Inc is 3.00, with a high of 3.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

3.000

Target Price

+91.08%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Mira Pharmaceuticals Inc

MIRA

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 6.33, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 2.24 and the support level at 1.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.41

Change

-0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.000

Buy

RSI(14)

50.796

Neutral

STOCH(KDJ)(9,3,3)

38.307

Sell

ATR(14)

0.153

Low Volatility

CCI(14)

-41.470

Neutral

Williams %R

62.500

Sell

TRIX(12,20)

0.841

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.624

Sell

MA10

1.616

Sell

MA20

1.524

Buy

MA50

1.428

Buy

MA100

1.437

Buy

MA200

1.282

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 5.22%, representing a quarter-over-quarter decrease of 79.55%. The largest institutional shareholder is The Vanguard, holding a total of 117.82K shares, representing 0.62% of shares outstanding, with 13.16% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Aminov (Erez)

844.70K

+7.99%

Bay Shore Trust

2.54M

McNulty (Brian Patrick)

789.05K

Candace Shira Associates, LLC

359.40K

-1.10%

Geode Capital Management, L.L.C.

135.29K

-0.09%

The Vanguard Group, Inc.

Star Investors

117.82K

Suncoast Equity Management, LLC.

103.29K

Shekhat (Denil Nanji)

41.67K

First American Bank

20.00K

State Street Investment Management (US)

49.10K

Risk Assessment

Currency: USD Updated: 2025-11-05

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.47. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.